Success Metrics

Clinical Success Rate

33.3%

Based on 1 completed trials

Completion Rate

33%(1/3)

Active Trials

0(0%)

Results Posted

300%(3 trials)

Terminated

2(67%)

Phase Distribution

Ph phase_3

67%

Ph phase_2

33%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution3 total trials

Phase 2Efficacy & side effects

1(33.3%)

Phase 3Large-scale testing

2(66.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Completed(1)

Terminated(2)

Detailed Status

Terminated2

Completed1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

33.3%

Most Advanced

Phase 3

Trials by Phase

Phase 21 (33.3%)

Phase 32 (66.7%)

Trials by Status

terminated267%

completed133%

Recent Activity

0 active trials

Showing 3 of 3

terminatedphase_2

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

NCT02100891

completedphase_3

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

NCT00049517

terminatedphase_3

Leukemia Stem Cell Detection in Acute Myeloid Leukemia

NCT02927938

Clinical Trials (3)

Showing 3 of 3 trials

NCT02100891Phase 2

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors

Terminated

NCT00049517Phase 3

Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia

Completed

NCT02927938Phase 3

Leukemia Stem Cell Detection in Acute Myeloid Leukemia

Terminated

All 3 trials loaded

Drug Details

Intervention Type: PROCEDURE
Total Trials: 3